IONSIonis Pharmaceuticals, Inc.Finished
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Phlebotomy Dependent Polycythemia Vera
18Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
- +7.8
2 insiders sold shares within a month
Since Oct 16, 2026 · was worth 10, fading over time
Worry score18
Score over time
- Stage
- Phase 2
- Patients
- 50 (final count)
- Started
- Dec 30, 2021
- Main results expected
- Jun 26, 2025
- Fully finished
- Jun 2, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period
Measured over: Week 17 to Week 37
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-26, no fading
- insider_selling_cluster: base 10, now 7.8, since 2026-10-16, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05143957 · record last updated 2026-07-09 · checked 2026-11-09 06:30 UTC